Company Overview: Caymabay Therapeutics

Industry News

9 Mar

CymaBay Therapeutics to Present at Two Investor Conferences in March

NEWARK, Calif., March 09, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced that management will provide a corporate overview at the 29th Annual ROTH Conference, being held March 12-15, 2017...

Read more

7 Feb

CymaBay Therapeutics to Present at the 2017 BIO CEO & Investor Conference

NEWARK, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced that management will provide a corporate overview at the BIO CEO & Investor Conference, being held on February...

Read more

2 Feb

CymaBay Announces Pricing of Public Offering of Common Stock

NEWARK, Calif., Feb. 02, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet need, today announced the pricing of its previously announced underwritten public offering of 5,181,348 shares of its common stock at a...

Read more

5 Jan

CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate

NEWARK, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced that it has successfully concluded its scientific advice discussions with the European Medicines Agency (EMA) on the Phase...

Read more

7 Dec

CymaBay Therapeutics Announces the Initiation of its Next Phase 2 Study of Seladelpar (MBX-8025) in Patients with Primary Biliary Cholangitis

NEWARK, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat indications with high unmet medical need, today announced the initiation of a new Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC). PBC is an orphan...

Read more

6 Dec

CymaBay Therapeutics Announces that the Recommended International Nonproprietary Name for MBX-8025 is Seladelpar

NEWARK, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat indications with high unmet medical need, today announced that the World Health Organization (WHO) has recommended seladelpar as the designated international nonproprietary name for MBX-8025. As part of its...

Read more

28 Nov

CymaBay Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference

NEWARK, Calif., Nov. 28, 2016 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for indications with high unmet medical need, including rare and orphan diseases, today announced that management will participate in a fireside chat at the 28th Annual Piper Jaffray Healthcare...

Read more

9 Nov

CymaBay Reports Third Quarter 2016 Financial Results

NEWARK, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for indications with high unmet medical need, including rare and orphan diseases, today provided recent corporate highlights and announced financial results for the quarter and nine months ended September...

Read more

Page 1 of 712345...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address